Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
---|---|---|---|---|
Income Statement | ||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -643.00K | 0.00 | -560.00K | -529.00K |
EBITDA | -60.03M | -51.71M | -34.75M | -29.38M |
Net Income | -70.20M | -52.67M | -35.31M | -29.51M |
Balance Sheet | ||||
Total Assets | 86.07M | 114.91M | 35.73M | 16.00M |
Cash, Cash Equivalents and Short-Term Investments | 83.37M | 110.76M | 29.88M | 11.54M |
Total Debt | 823.00K | 1.08M | 674.00K | 637.00K |
Total Liabilities | 7.90M | 11.08M | 137.58M | 70.42M |
Stockholders Equity | 78.17M | 103.83M | -101.84M | -54.42M |
Cash Flow | ||||
Free Cash Flow | -61.36M | -51.17M | -34.79M | -28.09M |
Operating Cash Flow | -61.29M | -51.12M | -34.55M | -26.95M |
Investing Cash Flow | -20.41M | 15.87M | -246.00K | -1.13M |
Financing Cash Flow | 116.14M | 116.13M | 53.13M | 26.46M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $72.60M | ― | -69.96% | ― | -99.64% | -59.17% | |
55 Neutral | $72.33M | ― | -73.39% | ― | -27.33% | 34.66% | |
51 Neutral | $7.92B | -0.43 | -41.67% | 2.21% | 22.29% | -1.85% | |
48 Neutral | $120.43M | 10.83 | -94.59% | ― | -67.67% | -390.60% | |
42 Neutral | $36.40M | ― | -90.56% | ― | ― | 68.13% | |
42 Neutral | $35.53M | ― | -505.14% | ― | 16.14% | 31.01% | |
35 Underperform | $64.52M | ― | -96.33% | ― | ― | 7.72% |
OnKure Therapeutics has released promising early data from its PIKture-01 trial, showcasing the safety and efficacy of OKI-219, a selective PI3KαH1047R inhibitor, in treating various cancers. The drug demonstrated excellent tolerability and robust anti-tumor activity, with plans to advance its combination trials with fulvestrant. Investors can expect further insights and combination data by late 2025, positioning OnKure as a potential leader in precision oncology therapies.